Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
XMT-1660 Recombinant Human Monoclonal Antibody
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
产品信息
MA562645
应用
建议稀释比
已发表文章
产品规格
种属反应
Human
宿主/亚型
Human
/ IgG1, kappa
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
偶联物
形式
Liquid
浓度
1 mg/mL
纯化类型
Protein A/G
保存液
PBS, pH 7.4
内含物
no preservative
保存条件
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
运输条件
Ambient (domestic); Wet ice (international)
RRID
靶标信息
XMT-1660 also known as Emiltatug Ledadotin is an investigational antibody-drug conjugate (ADC) that targets B7-H4 an immune checkpoint ligand frequently overexpressed in various cancers including breast ovarian and endometrial tumors. Developed using Mersana's Dolasynthen platform XMT-1660 employs a site-specific drug-to-antibody ratio (DAR 6) optimized for antitumor efficacy. The ADC incorporates a DolaLock microtubule inhibitor payload with a controlled bystander effect specifically designed to enhance localized cytotoxicity while minimizing off-target effects. XMT-1660 has demonstrated promising antitumor activity in xenograft models of breast and ovarian cancers and is currently undergoing Phase 1 clinical trials to assess its safety tolerability and pharmacokinetic profile in patients with advanced solid tumors. These trials aim to validate XMT-1660's therapeutic potential as a targeted therapy reinforcing its strategy to leverage tumor antigen expression for targeted drug delivery in oncology.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
